|
[1]
|
［1］ OKAMURA T,TANIGUCHI S,OHKURA T,et al.Abnormally high expression of proteasome activator-gamma in thyroid neoplasm［J］. J Clin Endocrinol Metab， 2003， 88(3): 1374-1383.［2］ RODERICK M，HELEN G，PAOLO G, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and 〖STBX〗p53〖STBZ〗 mutations［J］. CANCER， 2005， 103(11): 2261-2268.［3］ KIMURA E T, NIKIFOROVA M N, ZHU Z, et al. High prevalence of 〖WTBX〗BRAF〖WTBZ〗 mutations in thyroid cancer genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma［J］. CANCER RESEARCH, 2003, 63: 1454-1457.［4］ PRATHIBHA R, WEAVER K L, CAPOBIANCO A J. Notch signalling in solid tumours: a little bit of everything but not all the time［J］. Nature， 2011（11）: 338-351.［5］ NIKIFOROVA M N, KIMURA E T, GANDHI M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas［J］. J Clin Endocrinol Metab, 2003, 88(11): 5399-5540.［6］ 沈铭昌.免疫组化在病理学中的应用进展与评价［J］.实用肿瘤杂志, 2002, 17（5）： 293-294.［7］ MAO I, LIU J, LI X, et al. REGgamma, a proteasome activator and beyond［J］. Cell Mol Life Sci， 2008， 65(24): 3971-80.［8］ NIKAIDO T, SHIMADA K, SHIBATA M, et al. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus［J］. Clin Exp Immunol, 1990, 79(2): 209-214.［9］ ROESSLER M, ROLLINGER W, MANTOVANI-ENDL L,et,al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis［J］. Mol Cell Proteomics, 2006, 5(11): 2092-2101.［10］ OKAMURA T, TANIGUCHI S, OHKURA T,et al. Abnormally high expression of proteasome activator-gamma in thyroid neoplasm［J］. J Clin Endocrinol Metab, 2003, 88(3): 1374-1383.［11］ SALVATORE G, NAPPI TC, SALERNO P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma［J］. Cancer Res, 2007, 67(21): 10148-10158.［12］ DAVIDOFFf A M, HEMDON J E, GLOVER N S, et al. Relation between 〖STBX〗p53〖STBZ〗 overexpression and established prognostic factors in breast cancer［J］. Surgery, 1991, 110(2): 259-264.［13］ ZHANG Z, ZHANG R.Proteasome activator PA28 gamma regulates 〖STBX〗p53〖STBZ〗 by enhancing its MDM2-mediated degradation［J］. EMBO J, 2008, 27(6): 852-64.［14］ PEYSSONNAUX C,EYCHENE A. The RAF/MEK/ERKpathway: new concepts of activation［J］. Biol Cell, 2001, 93: 53-62.［15］ DUESBERY N S,WEBB C P,VANDE W G F.MEK wars,a new front in the battle against cancer［J］. Nat Med, 1999(5): 736-742.［16］ PARR C,WATKINS G, JIANG W G. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumer clinicopathological parameters in human breast cancer［J］. Int J Med, 2004, 14(5): 779-786.［17］ QI R, AN H, YU Y, et al. 〖STBX〗NOTCH1〖STBZ〗 signaling inhibits growth of human hepatocellular crcinoma through induction of cell cycle arrest and apoptosis［J］. Cancer Res, 2003, 63: 8323-8329.
|
点击查看大图
下载: